A clinical trial by the World Health Organization (WHO) has found that Gilead Sciences Inc`s remdesivir had little or no effect on COVID-19 patients` length of hospital stay or chances of survival. 

In a preprint on the findings of the WHO’s Solidarity trial that was released on medRxiv, the  researchers wrote, "These Remdesivir, Hydroxychloroquine, Lopinavir and Interferon regimens appeared to have little or no effect on hospitalized COVID-19, as indicated by overall mortality, initiation of ventilation and duration of hospital stay." The results of the trial are yet to be reviewed and were uploaded on the preprint server medRxiv. 

The antiviral medication Remdesivir, developed for Ebola by US pharmaceutical company Gilead Sciences among the first to be used as a treatment for corona was one of the drugs recently used to treat US President Donald Trump`s coronavirus infection. Remdesivir received emergency use authorization from the U.S. Food and Drug Administration on May 1.

Corona is wreaking havoc in all over the world. The total number of  corona cases in world has reached to 38.9M. The pandemic has killed over 1.1 M people worldwide. 

Also Read: 

The second wave of Corona starts in Pak, Imran government issued a warning

Brazil: Police barred Prez's ally after they found money in his undergarments

I want to see if he can make it through the program: Trump on Joe Biden

US Military stated how infections can be prevented on flights